Skip to search formSkip to main content

Enadenotucirev

Known as: Chimeric Oncolytic Adenovirus Ad3/Ad11p Containing Two Deletions in the Viral Genome in the E3 Region (2444 bp) and in the E4 Region (24 bp) and 197 Non-homologous Nucleotides in the E2B Region, ColoAd1 Oncolytic Virus, EnAd 
A complex, replication-selective, E1B and partial E3 gene deleted, adenovirus type 11p (Ad11p)/Ad3 chimeric oncolytic virus with potential… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy (eNAD/EDM) is a neurodegenerative disorder… Expand
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2017
2017
BackgroundEnadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2017
2017
Enadenotucirev (EnAd) is a chimeric group B adenovirus isolated by bioselection from a library of adenovirus serotypes. It… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Oncolytic viruses exploit the cancer cell phenotype to complete their lytic life cycle, releasing progeny virus to infect nearby… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Spread of oncolytic viruses through tumor tissue is essential to effective virotherapy. Interstitial matrix is thought to be a… Expand
Is this relevant?
2014
2014
3103 Background: Enadenotucirev (E) is an Ad11/Ad3 group B adenovirus, selective for killing cancer cells with little or no… Expand
Is this relevant?
2012
2012
Attempts at developing oncolytic viruses have been primarily based on rational design. However, this approach has been met with… Expand
  • figure 1
Is this relevant?
2012
2012
High safety marks for Merck’s Gardasil Cuba tests prostate cancer vaccine HIV’s weak spot: V2 Unique anti-cancer agent… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Viral-mediated oncolysis is a novel cancer therapeutic approach with the potential to be more effective and less toxic… Expand
  • figure 1
  • table 1
  • table 3
  • table 2
  • table 4
Is this relevant?